While AI enables rapid drug creation for single individuals (n-of-1), the economic model is broken. It is not a commercial opportunity, creating an urgent societal challenge to develop new funding mechanisms like public-private partnerships to support these life-saving, non-scalable treatments.

The key to treating rare diseases is not just CRISPR technology but a regulatory shift toward an "umbrella" or "platform" strategy. This allows multiple drugs for different mutations to be tested under a single trial, drastically lowering costs and making it feasible to develop treatments for tiny patient populations.

The Orphan Drug Act successfully incentivized R&D for rare diseases. A similar policy framework is needed for common, age-related diseases. Despite their massive potential markets, these indications suffer from extremely high failure rates and costs. A new incentive structure could de-risk development and align commercial goals with the enormous societal need for longevity.

Renowned gene therapy pioneer Jim Wilson was forced to spin out ultra-rare disease programs into a new company after his initial venture failed to attract VC funding. This demonstrates that even elite scientific leadership cannot overcome investor disinterest in this segment without powerful, predictable government incentives like transferable priority review vouchers.

Unlike other right-to-try laws, Montana's new program allows biotech companies to generate a profit from selling experimental drugs before they receive full FDA approval. This creates a powerful new economic incentive and potential funding lifeline for smaller drug developers, changing the risk-reward calculation for bringing new therapies to market.

To fix market failures in drug development, sophisticated economic tools are used. Priority Vouchers let a firm fast-track an unrelated profitable drug, while Advanced Market Commitments (AMCs) are binding government promises to buy a future vaccine, guaranteeing a market where none exists.

Developing drugs for rare diseases demands a hands-on, dedicated approach. Unlike mass-market trials, it involves deep partnerships with busy academic centers and requires a company culture entirely focused on the unique, high-touch challenges of the space.

The commercial playbook for orphan drugs differs fundamentally from mass-market products. Success hinges on robust patient support services and bridge programs to ensure access, rather than the rebate-intensive battles for formulary placement common in competitive, large-market indications.

For fatal, untreatable diseases, the choice is not between a risky drug and a safe baseline. The paradigm shifts to a "risk-risk" choice: the risk of an experimental therapy versus the risk of doing nothing, which is certain death. This reframes the ethical calculus for regulators and developers.